Berry Wealth Group LP Makes New Investment in Edwards Lifesciences Corporation $EW

Berry Wealth Group LP bought a new position in shares of Edwards Lifesciences Corporation (NYSE:EW) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 2,589 shares of the medical research company’s stock, valued at approximately $202,000.

A number of other institutional investors have also recently bought and sold shares of the company. West Family Investments Inc. acquired a new position in Edwards Lifesciences in the second quarter valued at about $208,000. Skandinaviska Enskilda Banken AB publ increased its holdings in shares of Edwards Lifesciences by 15.2% in the second quarter. Skandinaviska Enskilda Banken AB publ now owns 1,090,051 shares of the medical research company’s stock valued at $85,253,000 after purchasing an additional 143,603 shares during the last quarter. Colonial Trust Advisors grew its holdings in Edwards Lifesciences by 0.4% in the 2nd quarter. Colonial Trust Advisors now owns 70,392 shares of the medical research company’s stock valued at $5,505,000 after buying an additional 291 shares in the last quarter. Norges Bank acquired a new position in Edwards Lifesciences in the 2nd quarter valued at $580,640,000. Finally, NINE MASTS CAPITAL Ltd acquired a new stake in shares of Edwards Lifesciences during the 2nd quarter worth approximately $31,284,000. Institutional investors and hedge funds own 79.46% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on EW. Oppenheimer downgraded Edwards Lifesciences from an “outperform” rating to a “market perform” rating in a research note on Wednesday, October 8th. Raymond James Financial upgraded Edwards Lifesciences from a “market perform” rating to an “outperform” rating and set a $96.00 target price on the stock in a report on Monday, November 3rd. Wells Fargo & Company lifted their target price on Edwards Lifesciences from $84.00 to $88.00 and gave the company an “overweight” rating in a research report on Thursday, August 7th. National Bankshares set a $92.00 target price on Edwards Lifesciences in a report on Friday, October 31st. Finally, Evercore ISI increased their target price on shares of Edwards Lifesciences from $88.00 to $92.00 and gave the company an “outperform” rating in a research report on Friday, October 31st. Three equities research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, ten have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Edwards Lifesciences presently has a consensus rating of “Moderate Buy” and a consensus price target of $91.39.

Edwards Lifesciences Stock Down 0.0%

Shares of EW opened at $86.74 on Friday. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.68 and a quick ratio of 3.87. The firm has a market cap of $50.34 billion, a P/E ratio of 12.48, a P/E/G ratio of 3.97 and a beta of 1.03. The stock has a 50 day simple moving average of $79.93 and a two-hundred day simple moving average of $78.45. Edwards Lifesciences Corporation has a 1 year low of $65.94 and a 1 year high of $87.40.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings results on Thursday, October 30th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.59 by $0.08. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.01%. The business had revenue of $1.55 billion during the quarter, compared to analyst estimates of $1.49 billion. During the same period in the prior year, the business posted $0.67 earnings per share. The company’s revenue was up 14.7% on a year-over-year basis. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS. Q4 2025 guidance at 0.580-0.640 EPS. On average, analysts forecast that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current fiscal year.

Insider Activity

In other news, VP Daniel J. Lippis sold 1,020 shares of the stock in a transaction dated Monday, November 10th. The shares were sold at an average price of $82.55, for a total transaction of $84,201.00. Following the completion of the sale, the vice president directly owned 22,002 shares in the company, valued at approximately $1,816,265.10. This represents a 4.43% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Scott B. Ullem sold 13,000 shares of the business’s stock in a transaction that occurred on Monday, November 10th. The shares were sold at an average price of $83.08, for a total value of $1,080,040.00. Following the transaction, the chief financial officer directly owned 39,898 shares in the company, valued at $3,314,725.84. This trade represents a 24.58% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Corporate insiders own 1.29% of the company’s stock.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.